Nijmegen, The Netherlands – May 31, 2010 – Syntarga B.V., the emerging Antibody-
Drug Conjugate (ADC) company, announces today that it entered into three additional
research collaborations since its March 2010 press release. These latest agreements
comprise a second collaboration with one of the two top-15 biopharma companies
announced in March and collaborations with a new, undisclosed top-tier biopharma
company, and a new, undisclosed mid-size biotechnology company.
ADCs will be evaluated by the Company's collaborators based on different Syntarga
proprietary Linker-Drug chemistries and a variety of collaborator antibodies. Syntarga
has generated a strong biological data package for its synthetic Linker-Drug payloads
with ADCs against multiple antigen targets, including Her2. The Company believes that
more research collaborations with established companies will be started in the near
future.
"The steadily increasing number of collaborations with top-tier biopharma companies
exemplify the growing interest in Syntarga’s proprietary Linker-Drug technology to
empower anticancer antibodies. These relationships help the Company with implementing
its strategy to bring ADC products based on its technology into the clinic as soon as
feasible." said Dr. Vincent de Groot, Chief Executive Officer of Syntarga.
About Syntarga BV
Syntarga is a privately held biopharmaceutical company engaged in the discovery and
development of proprietary Antibody-Drug Conjugate technology and products for the
treatment of cancer. The Company's cutting-edge chemistry capabilities and unique
know-how have led to the creation of its antibody empowering Potent Payload
Technology. Syntarga is leveraging its proprietary technologies and expertise to generate
and commercialize, alone and with partners, a portfolio of next generation Antibody-Drug
Conjugate products. For more information about Syntarga, visit its website at
www.syntarga.com.
